JP2001505773A - トリパレドキシン発現プラスミド、産生方法、使用、試験系および薬剤 - Google Patents
トリパレドキシン発現プラスミド、産生方法、使用、試験系および薬剤Info
- Publication number
- JP2001505773A JP2001505773A JP52624498A JP52624498A JP2001505773A JP 2001505773 A JP2001505773 A JP 2001505773A JP 52624498 A JP52624498 A JP 52624498A JP 52624498 A JP52624498 A JP 52624498A JP 2001505773 A JP2001505773 A JP 2001505773A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- tripaledoxin
- seq
- plasmid
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 9
- 238000012360 testing method Methods 0.000 title claims description 17
- 229940079593 drug Drugs 0.000 title claims description 5
- 239000003814 drug Substances 0.000 title claims description 5
- 239000013613 expression plasmid Substances 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 23
- 102000004190 Enzymes Human genes 0.000 claims abstract description 12
- 108090000790 Enzymes Proteins 0.000 claims abstract description 12
- 238000002955 isolation Methods 0.000 claims abstract description 8
- 241000222718 Crithidia fasciculata Species 0.000 claims abstract description 6
- 241000894006 Bacteria Species 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 71
- 102000004169 proteins and genes Human genes 0.000 claims description 63
- 210000004027 cell Anatomy 0.000 claims description 26
- 230000000694 effects Effects 0.000 claims description 26
- 150000001413 amino acids Chemical group 0.000 claims description 21
- 239000013612 plasmid Substances 0.000 claims description 19
- 102000003992 Peroxidases Human genes 0.000 claims description 18
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 108700001992 trypanothione Proteins 0.000 claims description 14
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- 230000014509 gene expression Effects 0.000 claims description 11
- 239000000523 sample Substances 0.000 claims description 9
- 108090000721 thyroid hormone receptors Proteins 0.000 claims description 9
- 108091034117 Oligonucleotide Proteins 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- 241000588724 Escherichia coli Species 0.000 claims description 6
- 230000003197 catalytic effect Effects 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 5
- 241000894007 species Species 0.000 claims description 5
- 239000000758 substrate Substances 0.000 claims description 5
- 241000223104 Trypanosoma Species 0.000 claims description 4
- 238000012546 transfer Methods 0.000 claims description 4
- 241000196324 Embryophyta Species 0.000 claims description 3
- 241000238631 Hexapoda Species 0.000 claims description 3
- 102000007456 Peroxiredoxin Human genes 0.000 claims description 3
- 238000004113 cell culture Methods 0.000 claims description 3
- 238000010353 genetic engineering Methods 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 108030002458 peroxiredoxin Proteins 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- LZMSXDHGHZKXJD-VJANTYMQSA-N trypanothione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H]1CSSC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(=O)NCCCNCCCCNC(=O)CNC1=O LZMSXDHGHZKXJD-VJANTYMQSA-N 0.000 claims 3
- 150000002019 disulfides Chemical class 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000000654 trypanocidal effect Effects 0.000 claims 1
- 239000002690 trypanocidal agent Substances 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 39
- 108020004414 DNA Proteins 0.000 description 18
- 239000000872 buffer Substances 0.000 description 17
- 238000003752 polymerase chain reaction Methods 0.000 description 16
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 230000006698 induction Effects 0.000 description 11
- PHDOXVGRXXAYEB-MANSERQUSA-N trypanothione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](CS)C(=O)NCC(=O)NCCCCNCCCNC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@@H](N)C(O)=O PHDOXVGRXXAYEB-MANSERQUSA-N 0.000 description 11
- 239000012634 fragment Substances 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 7
- 238000006722 reduction reaction Methods 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 108010079939 tryparedoxin Proteins 0.000 description 6
- 102000004316 Oxidoreductases Human genes 0.000 description 5
- 108090000854 Oxidoreductases Proteins 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 244000045947 parasite Species 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- 101150062179 II gene Proteins 0.000 description 3
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 3
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000012148 binding buffer Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000011544 gradient gel Substances 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- -1 peroxide Hydrogen peroxide Chemical class 0.000 description 3
- BQVCCPGCDUSGOE-UHFFFAOYSA-N phenylarsine oxide Chemical compound O=[As]C1=CC=CC=C1 BQVCCPGCDUSGOE-UHFFFAOYSA-N 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 108010054902 tryparedoxin peroxidase Proteins 0.000 description 3
- 208000000230 African Trypanosomiasis Diseases 0.000 description 2
- 206010001935 American trypanosomiasis Diseases 0.000 description 2
- 208000002109 Argyria Diseases 0.000 description 2
- 241000244203 Caenorhabditis elegans Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 208000024699 Chagas disease Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 101150017040 I gene Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 241000737052 Naso hexacanthus Species 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 101710118538 Protease Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000002933 Thioredoxin Human genes 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 241000223109 Trypanosoma cruzi Species 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 208000029080 human African trypanosomiasis Diseases 0.000 description 2
- 244000052637 human pathogen Species 0.000 description 2
- 125000001867 hydroperoxy group Chemical group [*]OO[H] 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 201000002612 sleeping sickness Diseases 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- RWVGQQGBQSJDQV-UHFFFAOYSA-M sodium;3-[[4-[(e)-[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfonatophenyl)methyl]azaniumylidene]-2-methylcyclohexa-2,5-dien-1-ylidene]methyl]-n-ethyl-3-methylanilino]methyl]benzenesulfonate Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=C1 RWVGQQGBQSJDQV-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 2
- 108060008226 thioredoxin Proteins 0.000 description 2
- 229940094937 thioredoxin Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- DGWDWLRHFOUZCX-UHFFFAOYSA-N (25R)-26-[(D-Glucopyranosyl)oxy]-2hydroxyfurosta-5,20(22)-dien-3yl O-D-glucopyranosyl-(1‘Â∆3)-O-D-glucopyranosyl-(1‘Â∆2)-O-[D-xylopyranosyl-(1‘Â∆3)]-O-D-glucopyranosyl-(1‘Â∆4)-D-ga Natural products O1C(CO)C(O)C(O)C(O)C1OCC(C)CCC(O1)=C(C)C(C2(CCC3C4(C)CC5O)C)C1CC2C3CC=C4CC5OC(C(C1O)O)OC(CO)C1OC(C1OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OCC(O)C(O)C1O DGWDWLRHFOUZCX-UHFFFAOYSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 239000007989 BIS-Tris Propane buffer Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000389783 Bulbonaricus brucei Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000222716 Crithidia Species 0.000 description 1
- 206010011668 Cutaneous leishmaniasis Diseases 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 230000003682 DNA packaging effect Effects 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 241000018427 Iphisa elegans Species 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 241000222727 Leishmania donovani Species 0.000 description 1
- 241000222736 Leishmania tropica Species 0.000 description 1
- 241000222698 Leptomonas Species 0.000 description 1
- 241000067829 Lilaeopsis brasiliensis Species 0.000 description 1
- 102000003896 Myeloperoxidases Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- 108010083873 NADPH peroxidase Proteins 0.000 description 1
- ARFHIAQFJWUCFH-IZZDOVSWSA-N Nifurtimox Chemical compound CC1CS(=O)(=O)CCN1\N=C\C1=CC=C([N+]([O-])=O)O1 ARFHIAQFJWUCFH-IZZDOVSWSA-N 0.000 description 1
- 102000010410 Nogo Proteins Human genes 0.000 description 1
- 108010077641 Nogo Proteins Proteins 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 241000224565 Phytomonas Species 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000377427 Sarcotragus fasciculatus Species 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 241001061127 Thione Species 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 101710159478 Thioredoxin-like protein Proteins 0.000 description 1
- 241001442399 Trypanosoma brucei gambiense Species 0.000 description 1
- 241000223107 Trypanosoma congolense Species 0.000 description 1
- 206010047505 Visceral leishmaniasis Diseases 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- HHKZCCWKTZRCCL-UHFFFAOYSA-N bis-tris propane Chemical compound OCC(CO)(CO)NCCCNC(CO)(CO)CO HHKZCCWKTZRCCL-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 230000007412 host metabolism Effects 0.000 description 1
- 150000002432 hydroperoxides Chemical class 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 201000000626 mucocutaneous leishmaniasis Diseases 0.000 description 1
- 229960002644 nifurtimox Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- RYVMUASDIZQXAA-UHFFFAOYSA-N pyranoside Natural products O1C2(OCC(C)C(OC3C(C(O)C(O)C(CO)O3)O)C2)C(C)C(C2(CCC3C4(C)CC5O)C)C1CC2C3CC=C4CC5OC(C(C1O)O)OC(CO)C1OC(C1OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OCC(O)C(O)C1O RYVMUASDIZQXAA-UHFFFAOYSA-N 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000006965 reversible inhibition Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.トリパノチオン(T(SH)2)の還元当量をペルオキシレドキシンに転 移させる能力を特徴とするタンパク質。 2.トリパノソーマ科の一つの種から調製される、および/またはそれから単 離され得ることを特徴とする請求の範囲第1項記載のタンパク質。 3.調製および/または単離が遺伝子工学により、特に下記の配列、配列番号 :1のオリゴヌクレオチドまたはその一部により、あるいはプローブとしての以 下の配列、配列番号:1の部分配列、特にプローブが前記配列上の単一または二 重線の部分を特徴とする配列番号:1の部分配列により実施され得ることを特徴 とする請求の範囲第1項または第2項記載のタンパク質: 4.15〜19kDaの分子量を特徴とする先行する請求の範囲のいずれかに 記載のタンパク質。 5.請求の範囲第3項記載の配列番号:1のアミノ酸配列を包含するかまたは 有するタンパク質。 6.配列番号:2(図3)のアミノ酸配列を包含するかまたは有するタンパク 質。 7.WCPPCモチーフ(図3)と、トリパノチオン(T(SH)2)により タンパク質ジスルフィドの、特にペルオキシレドキシンの、特にトリパレドキシ ンペルオキシダーゼ(TXNPx)の還元を触媒することとを特徴とする、先行 する請求の範囲のいずれかに記載のタンパク質。 8.以下の、 (a)アミノ酸配列、配列番号:2(図3、位置1〜150)、 を有するか、または (b)当該(a)と相同であり、同数か、少ないか、わずかに少ないかまたは より多いアミノ酸を有し、そしてアミノ酸配列、配列番号:1または配列番号: 2を有するタンパク質をコードするオリゴヌクレオチドとハイブリダイゼーショ ン可能な(1M NaCl濃度および少なくとも25℃の温度で)オリゴヌクレ オチドによりコードされるアミノ酸配列を有する、タンパク質。 9.当該請求の範囲第8項記載の(a)と少なくとも70%、特に少なくとも 75%相同であるおよび/または配列番号:2とそのアミノ酸数が30個まで、 特に25個まで、好ましくは20個まで異なるアミノ酸配列を有する請求の範囲 第8項記載の(b)のタンパク質。 10.先行する請求の範囲第1項乃至第9項のいずれかに記載のタンパク質の 発現のための、そして当該タンパク質をコードする核酸を包含するプラスミド。 11.特にCrithidia fasciculataの請求の範囲第8項記載のタンパク質(トリ パレドキシン=TXN)をコードするDNA配列を含有する請求の範囲第10項 記載のプラスミド。 12.それ自体既知の方法での単離を目的として設計された請求の範囲第8項 記載のタンパク質(トリパレドキシン=TXN)の、機能的に有効な誘導体の発 現のためのプラスミドであって、当該誘導体をコードするDNA配列を含有する プラスミド。 13.該トリパレドキシンがHisタグにより誘導体化される、請求の範囲第 8項記載のタンパク質(トリパレドキシン=TXN)の機能的に活性な誘導体を コードするDNA配列を含有する請求の範囲第12項記載のプラスミド。 14.配列番号:1のオリゴヌクレオチドまたはその任意の一部により、ある いは請求の範囲第3項記載のプローブとしての配列番号:1の配列の部分配列に より、それ自体既知の方法で遺伝子工学により製造されることを特徴とする請求 の範囲第1項乃至第9項のいずれかに記載のタンパク質の製造方法。 15.該製造が請求の範囲第10項乃至第13項のいずれかに記載のプラスミ ド により実行されることを特徴とする請求の範囲第1項〜第9項のいずれかに記載 のタンパク質の製造方法。 16.宿主が細菌、真菌、酵母菌、植物細胞、昆虫細胞、哺乳類細胞または細 胞培養(異種発現)から成る群から選択されることを特徴とする請求の範囲第1 5項記載の方法。 17.大腸菌が宿主として用いられることを特徴とする請求の範囲第15項記 載の方法。 18.前記タンパク質の活性を阻害する阻害物質を試験し、回収することを目 的とする請求の範囲第1項乃至第9項のいずれかに記載の、あるいは請求の範囲 第14項乃至第17項のいずれかに記載の方法により得られるタンパク質の使用 。 19.請求の範囲第1項〜第9項のいずれかに記載の、または請求の範囲第1 4項〜第17項のいずれかに記載の方法により得られるタンパク質の触媒活性を 試験するための試験系であって、それぞれ、トリパノチオン(T(SH)2)、 トリパノチオンレダクターゼ(TR)、トリパレドキシンペルオキシダーゼ(T XNPx)、活性が試験されるタンパク質、そしてさらに、指示薬酵素としての ヒドロペルオキシド、媒介物質、および基質を含有または包含する試験系。 20.殺トリパノソーマ活性を有し、請求の範囲第1項乃至第9項のいずれか に記載のタンパク質、または請求の範囲第14項乃至第17項のいずれかに記載 の方法により得られるタンパク質の触媒活性を阻害する阻害物質を包含する薬剤 。 21.請求の範囲第17項または第18項に記載の使用により、および/また は請求の範囲第19項に記載の試験系を使用することにより得られることを特徴 とする請求の範囲第20項記載の薬剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96120015 | 1996-12-12 | ||
EP96120015.1 | 1996-12-12 | ||
PCT/EP1997/006983 WO1998026051A2 (en) | 1996-12-12 | 1997-12-12 | Tryparedoxin, expression plasmid, process of production, use, test system and pharmaceutical preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001505773A true JP2001505773A (ja) | 2001-05-08 |
JP2001505773A5 JP2001505773A5 (ja) | 2005-08-11 |
Family
ID=8223490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52624498A Ceased JP2001505773A (ja) | 1996-12-12 | 1997-12-12 | トリパレドキシン発現プラスミド、産生方法、使用、試験系および薬剤 |
Country Status (10)
Country | Link |
---|---|
US (3) | US6432671B1 (ja) |
EP (1) | EP0944718A2 (ja) |
JP (1) | JP2001505773A (ja) |
KR (1) | KR20000069395A (ja) |
AU (1) | AU746917B2 (ja) |
BR (1) | BR9714010A (ja) |
CA (1) | CA2275175A1 (ja) |
IL (1) | IL130272A0 (ja) |
NZ (1) | NZ335968A (ja) |
WO (1) | WO1998026051A2 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000069395A (ko) * | 1996-12-12 | 2000-11-25 | 프로헤 레오폴드 | 트리파레독신, 발현 플라스미드, 제조방법, 용도, 시험 시스템및 의약 제제 |
AU2003228450A1 (en) * | 2002-04-08 | 2003-10-27 | The Johns Hopkins University | Inhibition of tumor growth via peroxiredoxin 3 |
CN100547078C (zh) * | 2003-03-31 | 2009-10-07 | 诺维信股份有限公司 | 在缺乏酶的黑曲霉突变体中生产生物物质的方法 |
US7579153B2 (en) * | 2005-01-25 | 2009-08-25 | Population Genetics Technologies, Ltd. | Isothermal DNA amplification |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4942170A (en) * | 1988-05-27 | 1990-07-17 | The Rockefeller University | 2-(substituted methylidene)-N-[3-[piperidin-1-yl]propyl]hydrazine carboximidamides useful as antiparasitics |
KR20000069395A (ko) * | 1996-12-12 | 2000-11-25 | 프로헤 레오폴드 | 트리파레독신, 발현 플라스미드, 제조방법, 용도, 시험 시스템및 의약 제제 |
-
1997
- 1997-12-12 KR KR1019997005144A patent/KR20000069395A/ko not_active Application Discontinuation
- 1997-12-12 WO PCT/EP1997/006983 patent/WO1998026051A2/en not_active Application Discontinuation
- 1997-12-12 IL IL13027297A patent/IL130272A0/xx unknown
- 1997-12-12 NZ NZ335968A patent/NZ335968A/xx unknown
- 1997-12-12 BR BR9714010-4A patent/BR9714010A/pt not_active IP Right Cessation
- 1997-12-12 JP JP52624498A patent/JP2001505773A/ja not_active Ceased
- 1997-12-12 EP EP97954391A patent/EP0944718A2/en not_active Withdrawn
- 1997-12-12 AU AU58563/98A patent/AU746917B2/en not_active Ceased
- 1997-12-12 CA CA002275175A patent/CA2275175A1/en not_active Abandoned
-
1999
- 1999-06-11 US US09/330,914 patent/US6432671B1/en not_active Expired - Fee Related
-
2002
- 2002-07-12 US US10/193,795 patent/US20030082202A1/en not_active Abandoned
-
2004
- 2004-10-12 US US10/962,760 patent/US20050143559A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BR9714010A (pt) | 2000-05-09 |
AU5856398A (en) | 1998-07-03 |
EP0944718A2 (en) | 1999-09-29 |
NZ335968A (en) | 2000-12-22 |
US20030082202A1 (en) | 2003-05-01 |
IL130272A0 (en) | 2000-06-01 |
AU746917B2 (en) | 2002-05-02 |
US6432671B1 (en) | 2002-08-13 |
KR20000069395A (ko) | 2000-11-25 |
WO1998026051A3 (en) | 1998-11-19 |
WO1998026051A2 (en) | 1998-06-18 |
CA2275175A1 (en) | 1998-06-18 |
US20050143559A1 (en) | 2005-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Low et al. | Knowing when not to stop: selenocysteine incorporation in eukaryotes | |
Moskovitz et al. | Cloning the expression of a mammalian gene involved in the reduction of methionine sulfoxide residues in proteins. | |
Stein et al. | Chlamydomonas reinhardtii thioredoxins: structure of the genes coding for the chloroplastic m and cytosolic h isoforms; expression in Escherichia coli of the recombinant proteins, purification and biochemical properties | |
Kenny et al. | Bacterial expression, purification, and characterization of rat kidney-type mitochondrial glutaminase | |
IL180694A (en) | A toxin-removing substance that has the sub-activity of aflatoxin and its genetic coding | |
Tetaud et al. | Cloning, expression and reconstitution of the trypanothione-dependent peroxidase system of Crithidia fasciculata | |
Raychaudhuri et al. | Cloning and expression of the gene for soybean hydroxyisourate hydrolase. Localization and implications for function and mechanism | |
JP2022537010A (ja) | イソオイゲノールからのバニリンの生合成 | |
JP7387194B2 (ja) | イソオイゲノールからのバニリンの生合成 | |
Hirawake et al. | Human complex II (succinate-ubiquinone oxidoreductase): cDNA cloning of the flavoprotein (Fp) subunit of liver mitochondria | |
JP2001505773A (ja) | トリパレドキシン発現プラスミド、産生方法、使用、試験系および薬剤 | |
CN108977455B (zh) | 用于生产草酸脱羧酶的重组质粒、大肠杆菌表达系统及方法和应用 | |
JP2000236888A (ja) | β,β−カロテン15,15’−ジオキシゲナーゼ | |
Breithaupt et al. | Cloning and expression of (R)-hydroxynitrile lyase from Linum usitatissimum (flax) | |
Palmer et al. | Cloning and sequence analysis of the LPD-glc structural gene of Pseudomonas putida | |
Berwal et al. | Plasmodium falciparum: enhanced soluble expression, purification and biochemical characterization of lactate dehydrogenase | |
Chen et al. | Expression, purification, and characterization of a recombinant 5-lipoxygenase from potato tuber | |
Tamoi et al. | Molecular mechanisms of the resistance to hydrogen peroxide of enzymes involved in the Calvin cycle from halotolerant Chlamydomonas sp. W80 | |
Štefanková et al. | The thioredoxin system from Streptomyces coelicolor | |
KR101253505B1 (ko) | 철 결합 활성을 갖는 신규한 페리틴 및 이를 암호화하는 유전자 | |
WO1998026051A9 (en) | Tryparedoxin, expression plasmid, process of production, use, test system and pharmaceutical preparation | |
Platko et al. | Heterologous expression of Mytilus californianus foot protein three (Mcfp-3) in Kluyveromyces lactis | |
Barrett et al. | Overexpression in Escherichia coli and purification of the 6-phosphogluconate dehydrogenase of Trypanosoma brucei | |
JP2001524807A (ja) | トリパレドキシン−ペルオキシダーゼ | |
JPH11221081A (ja) | 耐熱性フルクトシルアミノ酸オキシダーゼ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041110 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041110 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080129 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20080701 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080812 |